Clinical Trials in Breast Cancer
Professor Cameron’s first degree was in mathematics from the University of Cambridge, and he received his medical degree in 1986 from St. George’s Hospital Medical School, London. After completing a fellowship and MSc in Clinical Oncology at the University of Edinburgh, he received a M.D. with distinction in 1997 and completed his training as a medical oncologist that same year. Prof. Cameron is a member of several professional societies including the American Society of Clinical Oncology & the European Society for Medical Oncology. He has also been a member of the EORTC task force on the use of growth factors in chemotherapy for solid tumours and lymphoma and a past chairman of the EORTC New Agent Committee. He is a past member of the Scottish medicines Consortium project and the Scottish short-life working group on the use of unlicensed cancer medicines.
He is active in a number of clinical trials in breast cancer. He is a member of the executive committee of the HERA adjuvant herceptin trial, and a member of the steering group for several UK adjuvant breast cancer trials (AZURE, OPTION, TACT, TANGO, MAMMO50, ARTEMIS, PERSEPHONE, ROSCO and TEAM) as well as the BIG APHINITY, ALTTO/NEO_ALTTO, BRAVO and AURORA studies. He is chief investigator on the recently reported UK trial adjuvant breast cancer trial, TACT2, and of BEATRICE, a global trial that tested the possible benefit of adjuvant bevacizumab in triple negative breast cancer. He jointly chairs the ENCHANT phase II study of an HSP90i in breast cancer.
Between November 2006 & June 2010 he was Director of the NIHR-funded National Cancer Research Networks, and at the end of 2009 took up a new post as Professor of Oncology at Edinburgh University and Director of Cancer Services in NHS Lothian. In this role he is the clinical director of the CRUK Edinburgh Centre , and has responsibility for oversight and strategy of clinical and translational research in cancer in Edinburgh. He continues his major clinical interest in breast cancer with an on-going clinical and translational research programme. He is a present and past member of several cancer research funding committees including INCA PHRC, PEAR, Cancer Research UK Science committee and from time to time NIHR funding bodies. He is also the Chief Scientist’s Office Clinical Cancer Research Champion in Scotland to act as a focal point for current and future clinical research in cancer in Scotland.
The CRUK Edinburgh Centre is committed to identifying potential new approaches to treating and preventing cancer. Being on the same campus as the NHS Edinburgh Cancer Centre, the Edinburgh Breast unit and the regional colorectal, neurological and urological surgical departments, it is in an ideal position to work closely with NHS cancer services. Many clinicians either run laboratory groups or collaborate with laboratory researchers to enable local patients to contribute to and benefit from new research into cancer.
There is a close-knit team of staff providing support for clinical trials in cancer patients, funded by Cancer Research UK, Experimental Cancer Medicine Centre (ECMC), Chief Scientist’s office via NHS Research&Development, and other local charities and funding sources. These staff are jointly managed to enable as many patients as possible to be offered the opportunity to enrol in clinical studies, from phase I “first in man” studies right through to late-stage randomised clinical trials.
Principal Investigator, Professor of Oncology, Centre Clinical Director and ECMC Lead